Amphotericin B in Lung Transplant Recipients

Micheli PA . Nova plantarum genera juxta Tournefortii methodum disposita. Florence, Italy: Bernardo Paperini, 1729.

Bennett JH . On the parasitic vegetable structures found growing in living animals. Transactions of the Royal Society of Edinburgh 1842; 15: 277–9.

Denning DW . Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 1996; 23: 608–15.

Kilburn KH . The innocuousness and possible therapeutic use of aerosol amphotericin B. Am Rev Respir Dis 1959; 80: 441–2.

Calvo V Borro JM Morales P Morcillo A Vincente R Tarrazona V . Antifungal prophylaxis during the early postoperative period of lung transplantation. Chest 1999; 115: 1301–4.

Reichenspurner H Gamberg P Nitschke M Valantine H Hunt S Oyer PE . Significant reduction in the number of fungal infections after lung-, heart—lung, and heart transplantation using aerosolized amphotericin B prophylaxis. Transplant Proc 1997; 29: 627–8.

Marra F Partovi N Wasan KM Kwong EH Ensom MHH Cassidy SM . Amphotericin B disposition after aerosol inhalation in lung transplant recipients. Ann Pharmacother 2002; 36:xxx.

Gerson SL Talbot GH Hurwitz S Strom BL Lusk EJ Cassileth PA . Prolonged granulocytopenia: The major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med 1984; 100: 345–51.

Koizumi T Kubo K Kaneki T Hanaoka M Hayano T Miyahara T . Pharmacokinetic evaluation of amphotericin B in lung tissue: Lung lymph distribution after intravenous injection and airspace distribution after aerosolization and inhalation of amphotericin B. Antimicrob Agents Chemother 1998; 42: 1597–600.

Gavalda J MonForte V Roman A Brava C Simo M Aguade S . Pharmacokinetics and distribution of nebulized amphotericin B (n-Amp) in lung transplantation (abstract #1925). In: Proceedings of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 29–9, 1999.

Beyer J Barzen G Risse G Weyer C Miksits K Dullenkopf K . Aerosol amphotericin B for prevention of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 1993; 37: 1367–9.

Manavathu EK Cutright JL Loebenberg D Chandrasekar PH . A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole, and posaconazole (SCH 56592). J Antimicrob Chemother 2000; 46: 229–34.

Pfaller MA Marco F Messer SA Jones RN . In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743, 792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagn Microbiol Infect Dis 1998; 30: 251–5.

Schwartz S Behre G Heinemann V Wandt H Schilling E Arning M . Aerosolized amphotericin B inhalation as prophylaxis of invasive aspergillus infections during prolonged neutropenia: Results of a prospective randomized multicenter trial. Blood 1999; 93: 3654–61.

Rex JH Pfaller MA Barry AL Nelson PW Webb CD . Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. NIAID Mycoses Study Group and the Candidemia Study Group. Antimicrob Agents Chemother 1995; 39: 40–4.